Comments on “The effects of norepinephrine in shockable cardiac arrest, a scoping review” Authors: Samantha Camp, Caitlin Williams, Ali Pourmand, Quincy K. Tran Published: 2025 ABSTRACT Norepinephrine in shockable cardiac arrest is a controversial topic. The review from Bouman et al. relies heavily on historical animal studies with limited human data, thus, their conclusion may not be clinically applicable. Current available data demonstrates significant heterogeneity, such as norepinephrine dosing and administration routes. Furthermore, a recent meta-analysis suggests no clear survival or neurologic benefit of norepinephrine over epinephrine. The assertions about neurologic outcomes, which were based on animal hemodynamics, were not supported by sufficient human evidence in the recent meta-analysis. Overall, the authors’ conclusions may be too much of an overreach, due to given the variability and limitations of the included studies, warranting cautious interpretation. Dear Editors: We read with great interest, “The effects of norepinephrine in shockable cardiac arrest, a scoping review” by Bouman et al. [1], and we would like to congratulate the authors on their recent publication in the Scandinavian Journal of Trauma, Resuscitation, and Emergency Medicine. The authors’ review of available research on norepinephrine use in cardiac arrest is an important and timely task, and we commend them for their efforts. However, we believe it is important to highlight some concerns regarding the content and heterogeneity of the studies included and the conclusions presented based on the included literature. While we recognize that this manuscript is a scoping review, we do have some concerns about the included studies. Although the authors acknowledge that many of the included studies were historical and predominantly animal-based (13 animal studies compared with only 5 human studies), we believe it would be valuable for readers to better clarify how this limitation impacts the interpretation and applicability of the findings. A major discussion point of the authors is the effect of norepinephrine administration on myocardial and cerebral hemodynamics. Their evidence for this discussion point is based solely in animal studies, many of which have limited sample sizes and are from the 1980s and 1990s, making them nearly 40 years old. While translational research and preliminary animal studies are important and necessary, we caution against strong conclusions for extrapolating the use of norepinephrine from animal studies to humans without supporting evidence. Another concern with the included studies is the presence of a case report [2]. Given that a single case report represents the lowest level of evidence, and very limited generalizability, including this study alongside higher-quality evidence may overstate its influence and weaken the overall strength of their conclusions. We do, however, appreciate the role of case reports in hypothesis generation and description of rare presentations. Our second main concern is the heterogeneity of norepinephrine use in the included studies. Dosages of norepinephrine varied significantly between the included studies, from 10 ug/kg [3, 4] to 200 ug/kg [5, 6] to non-weight-based dosing at 1 mg [7–9] and 11 mg [10]. In addition to the substantial variability in dosing, there was also marked heterogeneity in the route of administration across the included studies. The majority evaluated intravenous administration; however, several notable exceptions were present, including one outdated investigation of intracardiac delivery [9], two studies assessing endobronchial administration of norepinephrine [3, 4], and one examining continuous infusion [11]. Despite these differences, there is even further variance in norepinephrine use. One study describes using norepinephrine as an adjunct to epinephrine and isoprenaline [9]. Comparison groups for these studies also were inconsistent, with most studies comparing norepinephrine to epinephrine use, while one evaluated norepinephrine use compared to no intervention [9]. Given that current Advanced Life Support guidelines from the International Liaison Committee on Resuscitation still recommend epinephrine use [12], even in shockable cardiac arrest, comparing norepinephrine to no intervention does not adequately provide comparison to the standard of care. Since there was significant variability in how norepinephrine and comparators were used across studies, integrating these results requires careful interpretation and appropriate weighting to avoid overgeneralization. Lastly, we would like to express our concern in the authors’ discussion of norepinephrine’s role in neurologic outcomes, which they based on optimization of myocardial and cerebral hemodynamics. While we previously noted our concerns about these studies being solely animal-based, we also believe that extrapolating these results to neurological outcomes extends beyond the scope of the presented evidence. A recently published meta-analysis on this topic shows that with the current landscape of data, there is not enough information to support favorable survival or neurological outcomes with norepinephrine use compared to epinephrine in the post-cardiac arrest state [13]. With this in mind, we believe that the authors’ conclusions about neurologic outcomes were asserted too definitively given the limited and inconsistent evidence available in the included studies. We would like to thank the authors for their contributions to the field of norepinephrine use and its role in cardiac arrest care, highlighting the missing literature on this current topic, and presenting topics for future study.